JP2020531537A - カナキヌマブの使用 - Google Patents

カナキヌマブの使用 Download PDF

Info

Publication number
JP2020531537A
JP2020531537A JP2020511441A JP2020511441A JP2020531537A JP 2020531537 A JP2020531537 A JP 2020531537A JP 2020511441 A JP2020511441 A JP 2020511441A JP 2020511441 A JP2020511441 A JP 2020511441A JP 2020531537 A JP2020531537 A JP 2020531537A
Authority
JP
Japan
Prior art keywords
canakinumab
dose
patient
months
hscrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020511441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531537A5 (enExample
Inventor
トゥレン，トム
ブッシュ，クリストファー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020531537A publication Critical patent/JP2020531537A/ja
Publication of JP2020531537A5 publication Critical patent/JP2020531537A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020511441A 2017-08-25 2018-08-24 カナキヌマブの使用 Withdrawn JP2020531537A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549971P 2017-08-25 2017-08-25
US62/549,971 2017-08-25
US201762584380P 2017-11-10 2017-11-10
US62/584,380 2017-11-10
PCT/IB2018/056468 WO2019038740A1 (en) 2017-08-25 2018-08-24 USE OF CANAKINUMAB

Publications (2)

Publication Number Publication Date
JP2020531537A true JP2020531537A (ja) 2020-11-05
JP2020531537A5 JP2020531537A5 (enExample) 2021-09-09

Family

ID=63643018

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511441A Withdrawn JP2020531537A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用
JP2020511450A Withdrawn JP2020531539A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020511450A Withdrawn JP2020531539A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用

Country Status (5)

Country Link
US (3) US20200239564A1 (enExample)
EP (2) EP3710476A1 (enExample)
JP (2) JP2020531537A (enExample)
TW (2) TW201919695A (enExample)
WO (2) WO2019038740A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040953A (zh) * 2018-03-09 2020-12-04 布赖汉姆妇女医院 用于心血管疾病的组合治疗
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
CN113491820A (zh) * 2021-07-30 2021-10-12 复旦大学附属中山医院 涂层Canakinumab的药物球囊的制备及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
BR112014007253A2 (pt) 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta

Also Published As

Publication number Publication date
US20240043525A1 (en) 2024-02-08
EP3710475A1 (en) 2020-09-23
EP3710476A1 (en) 2020-09-23
US20200199220A1 (en) 2020-06-25
TW201919695A (zh) 2019-06-01
JP2020531539A (ja) 2020-11-05
US20200239564A1 (en) 2020-07-30
WO2019038737A1 (en) 2019-02-28
TW201919696A (zh) 2019-06-01
WO2019038740A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
JP7481071B2 (ja) 対象の心血管イベントのリスクを低減する方法
Rose et al. Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents
Lin et al. Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases
Tousoulis et al. Pathophysiology of atherosclerosis: the role of inflammation
Paquette et al. Cardiovascular disease, inflammation, and periodontal infection.
Morel et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb‐IIIa antagonists
Gailani et al. Targeting factor XI and factor XIa to prevent thrombosis
Ames et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome.
Garlapati et al. Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF-β1–driven fibrotic remodeling in ischemic heart failure
Orsi et al. Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial
JP2011507560A (ja) 血管機能を変化させる疾病の診断および治療ツール
Comarmond et al. Findings of cardiac magnetic resonance imaging in asymptomatic myocardial ischemic disease in Takayasu arteritis
US20240043525A1 (en) Use of canakinumab
CA3126202A1 (en) Diagnosis or prognosis of postsurgical adverse events
Kwaśny-Krochin et al. Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation
Sakuma et al. Myeloid-related protein-8/14 in acute coronary syndrome
Park et al. Aging-induced isoDGR-modified fibronectin activates monocytic and endothelial cells to promote atherosclerosis
Uematsu et al. Sustained myocardial production of stromal cell-derived factor-1α was associated with left ventricular adverse remodeling in patients with myocardial infarction
Kölmel et al. Potential involvement of osteopontin in inflammatory and fibrotic processes in pulmonary embolism and chronic thromboembolic pulmonary hypertension
Van Dijk et al. Association between fibrinogen and fibrinogen γ’and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study
Liu et al. Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina
Martínez‐Dolz et al. What is the best biomarker for diagnosis of rejection in heart transplantation?
Zhang et al. TXNIP aggravates cardiac fibrosis and dysfunction after myocardial infarction in mice by enhancing the TGFB1/Smad3 pathway and promoting NLRP3 inflammasome activation: TXNIP aggravates MI-induced cardiac remodelling
CA3202095A1 (en) Inhibitors of the tissue factor-protease activated receptor 2 (tf-par2) signaling pathway for use in the treatment or prevention of heart failure (hf) and associated or resulting diseases
Emadi et al. Diagnosis and management of venous thromboembolism: an update a decade into the new millennium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210727

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210924